Faro AI lands $37M to streamline clinical trial operations
San Diego-based Faro AI has raised $37 million in a Series B round to expand its platform that applies artificial intelligence to accelerate clinical trial execution. The company focuses on the post-discovery phase, aiming to reduce the time and cost of patient recruitment and trial management.
The Series B financing will support expansion of Faro AI's technology, which targets the operational side of clinical research rather than the discovery of new compounds. By concentrating on the post-discovery phase, the company addresses a critical bottleneck where many promising therapies encounter delays or fail to reach patients.
Patient recruitment and trial administration are historically labor-intensive and expensive components of drug development. Faro AI's use of artificial intelligence in these areas could help sponsors move studies forward more efficiently, potentially lowering the financial barriers that often slow the journey from laboratory breakthroughs to approved treatments.
If Faro AI's platform delivers meaningful efficiencies, patients awaiting new therapies could see shorter timelines between drug discovery and availability. Pharmaceutical companies and research organizations may also benefit from reduced trial costs, potentially enabling more studies to be conducted. However, the broader impact depends on whether AI-driven operational improvements translate into real-world results across diverse trial settings, and whether such tools remain accessible to smaller research sponsors.